Depression News and Research

Latest Depression News and Research

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

People of diverse communities are at increased risk for depression and suicide

Americans do not believe that they know much about depression, but are highly aware of the risks of not receiving care, according to a survey released by the National Alliance on Mental Illness (NAMI).

11 Dec 2009

NIH launches a $37 million program to reduce obesity

The National Institutes of Health is launching a $37 million program that will use findings from basic research on human behavior to develop more effective interventions to reduce obesity.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Psychologists can help people deal with anxiety and depression symptoms more effectively

From Thanksgiving to New Year's, there are many wishes for everyone to have a blissful and celebratory holiday season. But for many people, the holidays bring more misery than mirth, particularly at a time when the ailing economy can't seem to recover quickly enough and money worries remain on people's minds.

10 Dec 2009

Computer-based intervention reduces anxiety and depression among people with facial disfigurement

Using Face IT - a new computer-based teaching aid that includes interactive videos - can reduce anxiety, depression and appearance concerns among people with facial disfigurement.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

Experts call on Europe's policy makers to take urgent action against preventable strokes

A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year

9 Dec 2009

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

A depression drug created and patented by a team of University of South Florida researchers is at the center of major deal between global pharmaceutical company AstraZeneca PLC and Targacept, Inc., earning the university its potentially most lucrative patent royalties to date.

9 Dec 2009

Doctors around the world join the battle against human trafficking

Doctors At War, a newly formed 501(c)3 organization, is putting out a call-to-action for doctors worldwide to join them in the fight against the global sex trade. The long-term healthcare ramifications of the estimated 27 million victims throughout the world include post-traumatic stress disorder (PTSD), panic attacks, depression, and a host of other mental health issues along with countless physical health problems including HIV, STD's, malnutrition, sterility, and the effects of repeated physical trauma.

9 Dec 2009

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Psychological trauma leaves a trail of damage in a child's brain, say scientists at the Stanford University School of Medicine and Lucile Packard Children's Hospital. Their new study gives the first direct evidence that children with symptoms of post-traumatic stress suffer poor function of the hippocampus, a brain structure that stores and retrieves memories. The research helps explain why traumatized children behave as they do and could improve treatments for these kids.

9 Dec 2009

NeuroPace announces clinical trial results demonstrating the RNS System

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS- System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

9 Dec 2009

Biomarkers can be important in identifying PTSD symptoms, says researchers

Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) frequently experience high rates of PTSD along with symptoms of depression and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield new insights is to search for biomarkers -- indicators of a biological state that can be easily and reliably measured in people with an illness -- to see if their presence or absence can predict symptoms that an individual will experience and identify optimal treatment strategies.

9 Dec 2009

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.

9 Dec 2009

TLC Gift of Sight: A new financing option for corrective eye surgery

According to the Employee Benefits Research Institute, 30 million Americans use a Flexible Spending Account (FSA) to pay for qualified medical expenses, such as laser eye surgery.

8 Dec 2009

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS® System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

8 Dec 2009

Depression News and Research

Latest Depression News and Research

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

People of diverse communities are at increased risk for depression and suicide

NIH launches a $37 million program to reduce obesity

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Psychologists can help people deal with anxiety and depression symptoms more effectively

Computer-based intervention reduces anxiety and depression among people with facial disfigurement

Eli Lilly provides financial guidance for 2010

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Experts call on Europe's policy makers to take urgent action against preventable strokes

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

Doctors around the world join the battle against human trafficking

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

NeuroPace announces clinical trial results demonstrating the RNS System

Biomarkers can be important in identifying PTSD symptoms, says researchers

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

TLC Gift of Sight: A new financing option for corrective eye surgery

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in